Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer
Background. Partial cross-resistance to paclitaxel and docetaxel has been demonstrated in pre-clinical studies.
Patients and methods. We retrospectively evaluated the efficacy of weekly paclitaxel 80 mg/m2 in 82 patients with docetaxel-resisitant metastatic breast cancer. Docetaxel resistance was classified into primary resistance, defined as progressive disease while receiving docetaxel, and secondary resistance, defined as progression after achievement of a documented clinical response to docetaxel. Secondary resistance was subclassified according to the interval between the final infusion of docetaxel and the start of weekly paclitaxel into: (1) short interval, ≦120 days, and (2) long interval, >120 days.
Results. The response rate of the 82 patients was 19.5% (95% confidence interval, 10.8–27.9%). The response rate according to the docetaxel resistance category was: primary resistance (n=24), 8.3%; secondary resistance (n=58), 24.1% (short interval [n=39], 17.9%, and long interval, [n=19], 36.8%). The differences in response rates among the three categories were statistically significant (p=0.0247, Cochran–Mantel–Haenszel test). The interval between from the final docetaxel infusion and disease progression were predictors for response of weekly paclitaxel.
Conclusion. Weekly paclitaxel is modestly effective and safe in docetaxel-resistant metastatic breast cancer patients. However, weekly paclitaxel should not be recommended for primary resistance patients with docetaxel.
Keywordsdocetaxel metastatic breast cancer paclitaxel predictive factor resistance taxane
metastatic breast cancer
Pivot, X, Asmar, L, Hortobagyi, GN 1999The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-reistant breast cancerInt J Oncol15381386PubMedGoogle Scholar Sparano, JA 2000Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trialsClin Breast Cancer13240CrossRefPubMedGoogle Scholar Schiff, PB, Fant, J, Horwitz, SB 1979Promotion of microtubule assembly in vitro by taxolNature277665667PubMedGoogle Scholar Schiff, PB, Horwitz, SB 1980Taxol stabilizes microtubules in mouse fibroblast cellsProc Natl Acad Sci USA7715611565PubMedGoogle Scholar Schiff, PB, Horwitz, SB 1981Taxol assembles tubuin in the absence of exogenous guanosine 5′-triphospahate or micro tubule-associated proteinsBiochemistry2032473252PubMedGoogle Scholar Jordan, MA, Toso, RJ, Wilson, L 1993Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrationProc Natl Acad Sci USA9095529556PubMedGoogle Scholar Ringel, I, Horwitz, SB 1991Studies with RPR 56976 (Taxotere): a semisynthetic analogue of TaxolJ Natl Cancer Inst83288291PubMedGoogle Scholar Haldar, S, Basu, A, Croce, C 1997Bcl-2 is the guardian of microtuble integrityCancer Res57229233PubMedGoogle Scholar Riou, JF, Petitgenet, O, Combeau, C, Lavelle, F 1994Cellular uptake and efflux of docetaxel and paclitaxel in P388 cell lineProc Am Assoc Cancer Res35385Google Scholar Verweij, J, Clavel, M, Chevallier, B 1994Paclitaxel (taxol) and docetaxel (taxotere): not simply two of a kindAnn Oncol5495505PubMedGoogle Scholar Alexandre, J, Bleuzen, P, Bonneterre, J, Sutherland, W, Misset, JL, Guastalla, J, Viens, P, Faivre, S, Chahine, A, Spielman, M, Bensmaine, A, Marty, M, Mahjoubi, M, Cvitkovic, E 2000Factors predicting for efficacy and safety of docetaxel in a compassionate use cohort of 825 heavily pretreated advanced breast cancer patientsJ Clin Oncol18562573PubMedGoogle Scholar Ando, M, Watanabe, T, Nagata, K, Narabayashi, M, Adachi, I, Katsumata, N 2001Efficacy of docetaxel 60 mg/m2in patients with metastatic breast cancer according to the status of anthracycline resistanceJ Clin Oncol19336342PubMedGoogle Scholar Adachi, I, Watanabe, T, Takashima, S, Narabayashi, M, Horikoshi, N, Aoyama, H, Taguchi, T 1996A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancerBr J Cancer73210216PubMedGoogle Scholar Ravdin, PM, Burris, HAIII, Cook, G, Eisenberg, P, Kane, M, Bierman, WA, Mortimer, J, Genevois, E, Bellet, RE 1995Phase II of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancerJ Clin Oncol1328792885PubMedGoogle Scholar Seidman, AD, Hudis, CA, Albanel, J, Tong, W, Tepler, I, Currie, V, Moynahan, ME, Theodoulou, M, Gollub, M, Baselga, J, Norton, L 1998Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancerJ Clin Oncol1633533361PubMedGoogle Scholar Perez, EA, Vogel, CL, Irwin, DH, Kirshner, JJ, Patel, R 2001Multicenter phase II trial of weekly paclitaxel in woman with metastatic breast cancerJ Clin Oncol1942164223PubMedGoogle Scholar Lin, YC, Chang, HK, Wang, CH, Chen, JS, Liaw, CC 2000Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracycline and paclitaxel: partial cross-resistance between paclitaxel and docetaxelAnti-Cancer Drugs11617621PubMedGoogle Scholar Valero, V, Jones, SE, Hoff, DD, Boosner, DJ, Mennel, RG, Ravadin, PM, Holmes, FA, Rahman, Z, Schottstaedt, MW, Erban, JK, Esparaza-Guerra, L, Earnhart, RH, Hortobagyi, GN, BurrisIII, HA 1998A phase II study of docetaxel in patients with paclitaxel-resitant metastatic breast cancerJ Clin Oncol1633623368PubMedGoogle Scholar Suzuma, T, Sakurai, T, Yoshimura, G, Umemura, T, Tamaki, T, Naito, Y 2000paclitaxel-induced remission in docetaxel refractory anthracycline-pretreated metastatic breast cancerAnti-Cancer Drugs11569571PubMedGoogle Scholar Ishitobi, M, Shin, E, Kikkawa, N 2001Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weekly paclitaxelInt J Clin Oncol65558PubMedGoogle Scholar
World Health Organization: WHO Handbook for reporting result of cancer treatment: offset publication 48, World Health Organization, Genova, 1979
Ardizzoni, A, Manegolod, C, Debruyne, C, Gaafar, R, Buchholz, E, Smit, EF, Lianes, P, ten Velde, G, Bosquee, L, Legrand, C, Neumaier, C, King, K 2003European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancerClin Cancer Res9143150PubMedGoogle Scholar Papadimitriou, CA, Fountzilas, G, Aravantios, G, Kalofonos, C, Moulopoulos, LA, Briassoulis, E, Gika, D, Dimopoulos, MA 2004Second-line chemotherapy with gemcitabine and cisplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group StudyGynecol Oncol92152159PubMedGoogle Scholar Sato, S, Kigawa, J, Kanamori, Y, Itamachi, H, Oishi, T, Shimada, M, Iba, T, Naniwa, J, Uegaki, K, Terakawa, N 2004Activity of docetaxel in paclitaxel-resistant ovarian cancer cellsCancer Chemother Pharmacol53247252PubMedGoogle Scholar Vanhoefer, U, Cao, S, Harstrick, A, Seeber, S, Rustum, YM 1997Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)Ann Oncol812211228PubMedGoogle Scholar